



News Release

Suven Obtains 1st Product Patent from US Patent office

*HYDERABAD, INDIA (December 27th, 2007) – Suven Life Sciences Ltd announces today that the US Patent office has granted Product Patent # US 7,297,711 to Suven. This is **Suven's first product patent granted in USA**. The granted claims of the patent include the class of selective Serotonin receptor affinity compounds discovered by Suven and are being developed as therapeutic agents. According to the invention '711 patent disclosure, the compounds are useful in the treatment of neuro-degenerative disorders like Alzheimer's, Parkinson, Schizophrenia and Huntington's.*

Suven has so far filed 29 product patent applications through PCT covering more than 145 countries, out of which 5 product patents are granted in various countries. There are several other patent applications from Suven Discovery Research are in the pipeline that have completed the administrative and technical diligence from the patent offices from major countries and would be granted shortly.

Suven has filed its first Investigational New Drug (IND) application with DCGI to conduct the clinical Phase-I study on their developmental candidate SUVN-502 and several candidates are in discovery pipeline undergoing GLP pre-clinical studies.

"We are very pleased by the issuance of this patent to Suven by US Patent office for our drug candidates that are being developed for CNS disorders which targets a \$18 billion potential market opportunity " says Venkat Jasti, CEO of Suven.

Suven Life Sciences is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are **first in class or best in class** therapies through the use of GPCR targets. The company has six internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's' disease and obesity in addition to developmental candidates in Alzheimer's disease and Schizophrenia.

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;